These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35855837)

  • 1. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
    Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
    Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
    PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
    BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination proficiency in ovarian and breast cancer patients.
    Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
    BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    Wu X; Wang Q; Liu P; Sun L; Wang Y
    Front Genet; 2022; 13():1026871. PubMed ID: 36468004
    [No Abstract]   [Full Text] [Related]  

  • 13. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
    Pawlyn C; Loehr A; Ashby C; Tytarenko R; Deshpande S; Sun J; Fedorchak K; Mughal T; Davies FE; Walker BA; Morgan GJ
    Leukemia; 2018 Jul; 32(7):1561-1566. PubMed ID: 29467487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.
    Liu Y; Li Y; Zhang MZ; Chen D; Leng Y; Wang J; Han BW; Wang J
    Cancer Genet; 2023 Apr; 272-273():35-40. PubMed ID: 36758499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    Pfarr N; Merkelbach-Bruse S
    Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity.
    Zhou A; Butt O; Ansstas M; Mauer E; Khaddour K; Ansstas G
    J Natl Compr Canc Netw; 2023 Jul; 21(7):688-693.e3. PubMed ID: 37433433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.